Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD

Neuroscience and Biobehavioral Reviews

Volumn 27, Issue 7, 2003, Pages 661-669

  Leo, Damiana ^a   Sorrentino, Eleonora ^a   Volpicelli, Floriana ^a   Eyman, Maria ^b   Greco, Dario ^a   Viggiano, Davide ^c   Di Porzio, Umberto ^a   Perrone Capano, Carla ^a,d  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Dopamine transporter; Dopamine uptake; Nurr1; RT PCR; Tyrosine hydroxylase

Indexed keywords

DOPAMINE RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ATTENTION DEFICIT DISORDER; CELL FUNCTION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC VARIABILITY; MALE; MESENCEPHALON; NERVE CELL DIFFERENTIATION; NONHUMAN; PATHOGENESIS; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES COMPARISON;

EID: 0242407441     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2003.08.009     Document Type: Conference Paper

References (61)

1. Swanson J., Castellanos F.X., Murias M. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol. 8:1998;263-271.
2. Faraone S.V., Doyle A.E. Genetic influences on attention deficit hyperactivity disorder. Curr Psychiatry Rep. 2:2000;143-146.
3. Kirley A., Hawi Z., Daly G., McCarron M., Mullins C., Millar N., Waldman I., Fitzgerald M., Gill M. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology. 27:2002;607-619.
4. Biederman J., Faraone S.V. Current concepts on the neurobiology of attention-deficit/hyperactivity disorder. J Atten Disord. 6:(Suppl 1):2002;S7-S16.
5. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res. 130:2002;65-71.
6. Swanson J.M., Volkow N.D. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res. 10:(130):2002;73-78.
7. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
8. Gainetdinov R.R., Wetsel W.C., Levin S.R., , et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:1999;397-401.
9. Russell V.A. The nucleus accumbens motor-limbic interface of the spontaneously hypertensive rat as studied in vitro by the superfusion slice technique. Neurosci Biobehav Rev. 4:2002;133-136.
10. Castellanos F.X., Tannock R. Neuroscience of attention-deficit/ hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 3:2002;617-628.
11. Swanson J.M., Flodman P., Kennedy J., Spence M.A., Moyzis R., Schuck S., Murias M., Moriarity J., Barr C., Smith M., Posner M. Dopamine genes and ADHD. Neurosci Biobehav Rev. 24:2000;21-25.
12. Reith M.E., Xu C., Chen N.H. Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol. 324:1997;1-10.
13. Jones S.R., Gainetdinov R.R., Wightman R.M. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 18:1998;1979-1986.
14. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 94:1998;127-152.
15. Trinh J.V., Nehrenberg D.L., Jacobsen J.P., Caron M.G. Wetsel differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience. 118:2003;297-310.
16. Krause K.H., Dresel S.H., Krause J., Kung H.F., Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 285:2000;107-110.
17. Dresel S., Krause J., Krause K.H., La Fougere C., Brinkbaumer K., Kung H.F., Hahn K., Tatsch K. Attention deficit hyperactivity disorder: binding of [99mTc] TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 27:2000;1518-1524.
18. Sagvolden T. Behavioural validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev. 24:2000;31-39.
19. Davids E., Zhang K., Tarazi F.I., Baldessarini R.J. Animal models of attention-deficit hyperactivity disorder. Brain Res Rev. 42:2003;1-21.
20. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res. 94:1998;163-171.
21. Carey M.P., Diewald L.M., Esposito F.J., Pellicano M.P., Gironi Carnevale U.A., Sergeant J.A., Papa M., Sadile A.G. Differential distribution, affinity and plasticity of dopamine D-1 and D-2 receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res. 94:1998;173-185.
22. Papa M., Diewald L., Carey M.P., Esposito F.J., Gironi Carnevale U.A., Sadile A.G. A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and a posterior hyperfunctioning mesocorticolimbic system. Behav Brain Res. 130:2002;171-179.
23. Russell V.A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res. 130:2002;191-196.
24. di Porzio U., Pernas-Alonso R., Perrone-Capano C. Development of dopaminergic neurons. Neuroscience Intelligence Unit. 1999;RG Landes Company, Austin TX.
25. Perrone-Capano C., Di Porzio U. Genetic and epigenetic control of midbrain dopaminergic neuron development. Int J Dev Biol. 44:2000;679-687.
26. Goridis C., Rohrer H. Specification of catecholaminergic and serotonergic neurons. Nat Rev Neurosci. 3:2002;531-541.
27. Perrone-Capano C., di Porzio U. Epigenetic factors and midbrain dopaminergic neurone development. Bioessays. 18:1996;817-824.
28. Perrone-Capano C., Da Pozzo P., di Porzio U. Epigenetic cues in midbrain dopaminergic neuron development. Neurosci Biobehav Rev. 24:2000;119-124.
29. Fiszman M.L., Zuddas A., Masana M.I., Barker J.L., di Porzio U. Dopamine synthesis precedes dopamine uptake in embryonic rat mesencephalic neurons. J Neurochem. 56:1991;392-399.
30. Zuddas A., Corsini G.U., Barker J.L., Kopin I.J., Di Porzio U. Specific reinnervation of lesioned mouse striatum by grafted mesencephalic dopaminergic neurons. Eur J Neurosci. 3:1991;72-85.
31. Perrone-Capano C., Tino A., di Porzio U. Target cells modulate dopamine transporter gene expression during brain development. Neuroreport. 5:1994;1145-1148.
32. Pernas-Alonso R., Morelli F., di Porzio U., Perrone-Capano C. Multiplex semi-quantitative reverse transcriptase-PCR of low abundance neuronal mRNAs. Brain Res Brain Res Protoc. 4:1999;395-406.
33. Steel M.C., Buckley N.J. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study. Mol Pharmacol. 43:1993;694-701.
34. Barkley R.A. A critique of current diagnostic criteria for attention deficit hyperactivity disorder: clinical and research implications. J Dev Behav Pediatr. 11:1990;343-352.
35. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J., Jensen P.S., Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet. 351:1998;429-433.
36. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 276:1997;248-250.
37. Castillo S.O., Baffi J.S., Palkovits M., Goldstein D.S., Kopin I.J., Witta J., Magnuson M.A., Nikodem V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci. 11:1998;36-46.
38. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., Burbach J.P., Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA. 95:1998;4013-4018.
39. Wallen A., Zetterstrom R.H., Solomin L., Arvidsson M., Olson L., Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp Cell Res. 253:1999;737-746.
40. Saucedo-Cardenas O., Conneely O.M. Comparative distribution of NURR1 and NUR77 nuclear receptors in the mouse central nervous system. J Mol Neurosci. 7:1996;51-63.
41. Xiao Q., Castillo S.O., Nikodem V.M. Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience. 75:1996;221-230.
42. Zetterstrom R.H., Williams R., Perlmann T., Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res. 41:1996;111-120.
43. Maione S., Siniscalco D., Galderisi U., de Novellis V., Uliano R., Di Bernardo G., Berrino L., Cascino A., Rossi F. Apoptotic genes expression in the lumbar dorsal horn in a model neuropathic pain in rat. Neuroreport. 13:2002;101-106.
44. Otter I., Conus S., Ravn U., Rager M., Olivier R., Monney L., Fabbro D., Borner C. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem. 273:1998;6110-6120.
45. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev. 78:1998;189-225.
46. Vallone D., Pignatelli M., Grammatikopoulos G., Ruocco L., Bozzi Y., Westphal H., Borrelli E., Sadile A.G. Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice. Behav Brain Res. 130:2002;141-148.
47. Elsworth J.D., Roth R.H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol. 144:1997;4-9.
48. Jones S.R., Gainetdinov R.R., Hu X.T., Cooper D.C., Wightman R.M., White F.J., Caron M.G. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci. 2:1999;649-655.
49. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience. 79:1997;323-327.
50. Baldo B.A., Kelley A.E. Cross-sensitization between cocaine and GBR 12909, a dopamine uptake inhibitor. Brain Res Bull. 27:1991;105-108.
51. Berger D.F., Sagvolden T. Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res. 94:1998;73-82.
52. Ueno K.I., Togashi H., Mori K., Matsumoto M., Ohashi S., Hoshino A., Fujita T., Saito H., Minami M., Yoshioka M. Behavioural and pharmacological relevance of stroke-prone spontaneously hypertensive rats as an animal model of a developmental disorder. Behav Pharmacol. 13:2002;1-13.
53. Bannon M.J., Pruetz B., Manning-Bog A.B., Whitty C.J., Michelhaugh S.K., Sacchetti P., Granneman J.G., Mash D.C., Schmidt C.J. Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci USA. 99:2002;6382-6385.
54. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res. 136:2002;267-275.
55. Le W., Conneely O.M., He Y., Jankovic J., Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 73:1999;2218-2221.
56. Xu P.Y., Liang R., Jankovic J., Hunter C., Zeng Y.X., Ashizawa T., Lai D., Le W.D. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 58:2002;881-884.
57. Matsushita N., Okada H., Yasoshima Y., Takahashi K., Kiuchi K., Kobayashi K. Dynamics of tyrosine hydroxylase promoter activity during midbrain dopaminergic neuron development. J Neurochem. 82:2002;295-304.
58. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem. 67:1996;443-462.
59. Waldman I.D., Rowe D.C., Abramowitz A., Kozel S.T., Mohr J.H., Sherman S.L., Cleveland H.H., Sanders M.L., Gard J.M., Stever C. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet. 63:1998;1767-1776.
60. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Franceschi D., Maynard L., Ding Y.S., Gatley S.J., Gifford A., Zhu W., Swanson J.M. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 43:2002;181-187.
61. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 97:2000;6850-6855.